NewsBenzingaFDAは、Filana Therapeuticsの新規薬剤申請の臨床保留を解除し、チューバー状硬化症複合体関連てんかんを持つ参加者に対する計画された第2a相試験を開始するための新薬承認申請を承認します FDAは、Filana Therapeuticsの新規薬剤申請の臨床保留を解除し、チューバー状硬化症複合体関連てんかんを持つ参加者に対する計画された第2a相試験を開始するための新薬承認申請を承認します Benzinga 2026.09.22 12:06 (GMT+0) Open on Benzinga Other news Dan Ives Says ‘Clearly Jensen Wants to Come Back as CEO’, Sees Potential Special Shareholder Meeting Telsey Advisory Group Maintains Market Perform on Kohl's, Raises Price Target to $25 Red Cat Q3 Revenue Contracts 42% in Q3, Analysts Cut Price Targets Citigroup Maintains Neutral on Petrobras Brasileiro, Lowers Price Target to $18.5 Nike Executive Says 2028 Will Be ‘A Challenging Year Financially’; Co. Expects Adjusted EPS To Decline Modestly In Fiscal 2028 From Fiscal 2027 Levels Lake Street Maintains Buy on Glass House Brands, Lowers Price Target to $3
Nike Executive Says 2028 Will Be ‘A Challenging Year Financially’; Co. Expects Adjusted EPS To Decline Modestly In Fiscal 2028 From Fiscal 2027 Levels